Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 6/20 | 0.38 |
| ▸ | TSHR | P16473 | 4/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.36 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.35 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.35 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.34 |
| ▸ | JAK2 | O60674 | 1/20 | 0.33 |
| ▸ | JAK1 | P23458 | 1/20 | 0.33 |
| ▸ | TYK2 | P29597 | 1/20 | 0.33 |
| ▸ | JAK3 | P52333 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5266232 | 0.73 | ALOX15 (0.42) | ALOX15CYP2D6TSHRALDH1A1CYP2C9 | |
| SCHEMBL28135479 | 0.72 | HRH3 (0.44) | ALOX15TSHRALDH1A1CYP2C9 | |
| SCHEMBL11387438 | 0.71 | ALDH1A1 (0.48) | ALDH1A1 | |
| SCHEMBL4336492 | 0.69 | CHRNA7 (0.40) | CYP2D6ALDH1A1CYP2C9CYP1A2CYP3A4 | |
| SCHEMBL3990816 | 0.69 | TRPV6 (0.46) | ALDH1A1CYP1A2SIGMAR1CYP2C19 | |
| SCHEMBL28290468 | 0.69 | ALOX15 (0.47) | ALOX15CYP2D6TSHRALDH1A1CYP2C9 | |
| SCHEMBL3982197 | 0.68 | MEN1 (0.50) | ALOX15ALDH1A1MAPK1 | |
| SCHEMBL1958015 | 0.68 | ALOX15 (0.52) | ALOX15CYP2D6TSHRALDH1A1CYP2C9 | |
| SCHEMBL14375259 | 0.68 | ALOX15 (0.52) | ALOX15CYP2D6TSHRALDH1A1CYP2C9 | |
| SCHEMBL3983242 | 0.68 | SIGMAR1 (0.37) | ALDH1A1SIGMAR1JAK2JAK1TYK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7482338-B2 | Non-amide nonanes | ASTRAZENECA AB (SE) | 2009-01-27 | — | — | US | claimed |
| EP-1673372-B1 | NON-AMIDE NONANES | ASTRAZENECA AB (SE) | 2007-05-30 | — | — | EP | claimed |
| US-20070043031-A1 | 4-(thiazol-5-ylmethyl)-1,4-diaza-bicyclo[3.2.2]nonane; 4-(2-phenyl-imidazol-5-ylmethyl)-1,4-diaza-bicyclo[3.2.2]nonane; nicotinic acetylcholine receptor agonists; diagnostics; amidation of 1,4-diaza-bicyclo[3.2.2]nonane, reduction and reductive amination | ASTRAZENECA AB (SE) | 2007-02-22 | — | — | US | claimed |
| US-7482338-B2 | Non-amide nonanes | ASTRAZENECA AB (SE) | 2009-01-27 | — | — | US | disclosed |
| US-7482338-B2 | Non-amide nonanes | ASTRAZENECA AB (SE) | 2009-01-27 | — | — | US | disclosed |
| EP-1673372-B1 | NON-AMIDE NONANES | ASTRAZENECA AB (SE) | 2007-05-30 | — | — | EP | disclosed |
| EP-1673372-B1 | NON-AMIDE NONANES | ASTRAZENECA AB (SE) | 2007-05-30 | — | — | EP | disclosed |
| US-20070043031-A1 | 4-(thiazol-5-ylmethyl)-1,4-diaza-bicyclo[3.2.2]nonane; 4-(2-phenyl-imidazol-5-ylmethyl)-1,4-diaza-bicyclo[3.2.2]nonane; nicotinic acetylcholine receptor agonists; diagnostics; amidation of 1,4-diaza-bicyclo[3.2.2]nonane, reduction and reductive amination | ASTRAZENECA AB (SE) | 2007-02-22 | — | — | US | disclosed |
| US-20070043031-A1 | 4-(thiazol-5-ylmethyl)-1,4-diaza-bicyclo[3.2.2]nonane; 4-(2-phenyl-imidazol-5-ylmethyl)-1,4-diaza-bicyclo[3.2.2]nonane; nicotinic acetylcholine receptor agonists; diagnostics; amidation of 1,4-diaza-bicyclo[3.2.2]nonane, reduction and reductive amination | ASTRAZENECA AB (SE) | 2007-02-22 | — | — | US | disclosed |
| EP-1673372-A1 | NON-AMIDE NONANES | AstraZeneca AB (SE) | 2006-06-28 | — | — | EP | disclosed |
| WO-2005030777-A1 | NON-AMIDE NONANES | ASTRAZENECA AB (SE) | 2005-04-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043031-A1 | 4-(thiazol-5-ylmethyl)-1,4-diaza-bicyclo[3.2.2]nonane; 4-(2-phenyl-imidazol-5-ylmethyl)-1,4-diaza-bicyclo[3.2.2]nonane; nicotinic acetylcholine receptor agonists; diagnostics; amidation of 1,4-diaza-bicyclo[3.2.2]nonane, reduction and reductive amination | CHRND, CHRNE, CHRM2 | ALOX15 2812/4885CYP2D6 537/4885TSHR 50/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.